PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Inclusion Criteria

• •Histological diagnosis of prostate cancer
• •Evidence of metastatic disease by radiologic criteria
• •Bone scan within 4 weeks of starting therapy
• •Creatinine within 2 weeks of registration, calculated creatinine clearance \> 60ml/min.
• •Minimum life expectancy of 6 months
• •Willingness to have pre-therapy PET scans performed within 2 weeks after registration and post therapy PET scan performed within 1 week after dose of Zometa (a total of 3 PET scans required)
• •Calculated creatinine clearance \> 50ml/min.
• •No prior Zoledronate therapy
• •Patients must have disease progression despite testosterone suppression (level\<50ng/ml); progression can be by rising PSA ( at least 2 values at least 2 weeks apart) or by new lesions on scans or progression of existing lesions on CT scan.
• •No concomitant systemic therapy for metastatic prostate cancer is allowed except LHRH analogue should be continued if necessary to maintain testosterone suppression.
• •No concomitant radiation therapy
• •Prior RT is allowed if completed at least 2 weeks prior to registration.
• •Presence of measurable or evaluable disease
• •If RT has been administered, disease outside the RT port is required.
• •Willingness to sign informed consent.
• •Registration and willingness to sign informed consent for separate PET protocol 2335 that describes the PET scan procedure.
• •Patients must have good oral hygiene which includes having a recent dental evaluation